Achaogen Inc (AKAO) Major Shareholder Buys $227,800.00 in Stock
Achaogen Inc (NASDAQ:AKAO) major shareholder Robert W. Duggan acquired 20,000 shares of the business’s stock in a transaction that occurred on Monday, March 12th. The shares were purchased at an average cost of $11.39 per share, with a total value of $227,800.00. Following the transaction, the insider now directly owns 6,255,148 shares of the company’s stock, valued at $71,246,135.72. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Achaogen Inc (AKAO) opened at $11.50 on Wednesday. The company has a market cap of $525.08, a PE ratio of -3.25 and a beta of 1.28. The company has a quick ratio of 4.83, a current ratio of 4.83 and a debt-to-equity ratio of 0.08. Achaogen Inc has a fifty-two week low of $9.83 and a fifty-two week high of $27.49.
Achaogen (NASDAQ:AKAO) last posted its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.21). The company had revenue of $1.87 million during the quarter, compared to the consensus estimate of $1.18 million. Achaogen had a negative return on equity of 83.14% and a negative net margin of 1,124.10%. equities research analysts forecast that Achaogen Inc will post -3.5 EPS for the current fiscal year.
Hedge funds have recently bought and sold shares of the company. Point72 Asset Management L.P. lifted its holdings in shares of Achaogen by 55.7% in the third quarter. Point72 Asset Management L.P. now owns 2,255,899 shares of the biopharmaceutical company’s stock worth $35,982,000 after acquiring an additional 806,899 shares during the last quarter. Artal Group S.A. lifted its holdings in shares of Achaogen by 25.0% in the third quarter. Artal Group S.A. now owns 250,000 shares of the biopharmaceutical company’s stock worth $3,988,000 after acquiring an additional 50,000 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Achaogen by 1,743.3% in the second quarter. The Manufacturers Life Insurance Company now owns 23,225 shares of the biopharmaceutical company’s stock worth $505,000 after acquiring an additional 21,965 shares during the last quarter. University of Notre Dame DU Lac lifted its holdings in shares of Achaogen by 49.9% in the third quarter. University of Notre Dame DU Lac now owns 155,654 shares of the biopharmaceutical company’s stock worth $2,483,000 after acquiring an additional 51,786 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in Achaogen by 375.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 18,648 shares of the biopharmaceutical company’s stock valued at $201,000 after buying an additional 14,725 shares during the last quarter. 77.37% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Achaogen Inc (AKAO) Major Shareholder Buys $227,800.00 in Stock” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/03/14/achaogen-inc-akao-major-shareholder-buys-227800-00-in-stock.html.
Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.